Title | Author | Year | SCOPUS | PUBMED | ISI | TCI | |
---|---|---|---|---|---|---|---|
1. | Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma. Association of diabetes mellitus and cholangiocarcinoma | Saengboonmee, C. Seubwai, W. Wongkham, C. Wongkham, S. |
2015 | ||||
2. | High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation | Saengboonmee, C. Seubwai, W. Pairojkul, C. Wongkham, S. |
2016 | ||||
3. | High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation | Phoomak, C. Vaeteewoottacharn, K. Silsirivanit, A. Saengboonmee, C. Seubwai, W. Sawanyawisuth, K. Wongkham, C. |
2017 | ||||
4. | Metformin exerts antiproliferative and anti-metastatic effects against cholangiocarcinoma cells by targeting STAT3 and NF-κB | Saengboonmee, C. Seubwai, W. Cha'on, U. Sawanyawisuth, K. Wongkham, C. |
2017 | ||||
5. | Prognostic biomarkers for cholangiocarcinoma and their clinical implications | Saengboonmee, C. Sawanyawisuth, K. Chamgramol, Y. Wongkham, S. |
2018 | ||||
6. | Overexpression of HexCer and LacCer containing 2-hydroxylated fatty acids in cholangiocarcinoma and the association of the increase of LacCer (d18:1-h23:0) with shorter survival of the patients | Silsirivanit, A. Phoomak, C. Seubwai, W. Saengboonmee, C. Wongkham, S. |
2019 | Count | 6 | 0 | 0 | 0 |
Title | Authors | Year | Publication name | Cited count | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
< 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | รวม | ||||||
1. | Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma. Association of diabetes mellitus and cholangiocarcinoma | Saengboonmee, C. Seubwai, W. Wongkham, C. Wongkham, S. |
2015 |
Cancer Epidemiology 3 (39), pp. 274-278 |
||||||||
2. | High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation | Saengboonmee, C. Seubwai, W. Pairojkul, C. Wongkham, S. |
2016 |
Scientific Reports (6), pp. |
||||||||
3. | High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation | Phoomak, C. Vaeteewoottacharn, K. Silsirivanit, A. Saengboonmee, C. Seubwai, W. Sawanyawisuth, K. Wongkham, C. |
2017 |
Scientific Reports (7), pp. |
||||||||
4. | Metformin exerts antiproliferative and anti-metastatic effects against cholangiocarcinoma cells by targeting STAT3 and NF-κB | Saengboonmee, C. Seubwai, W. Cha'on, U. Sawanyawisuth, K. Wongkham, C. |
2017 |
Anticancer Research 1 (37), pp. 115-123 |
||||||||
5. | Prognostic biomarkers for cholangiocarcinoma and their clinical implications | Saengboonmee, C. Sawanyawisuth, K. Chamgramol, Y. Wongkham, S. |
2018 |
Expert Review of Anticancer Therapy 6 (18), pp. 579-592 |
||||||||
6. | Overexpression of HexCer and LacCer containing 2-hydroxylated fatty acids in cholangiocarcinoma and the association of the increase of LacCer (d18:1-h23:0) with shorter survival of the patients | Silsirivanit, A. Phoomak, C. Seubwai, W. Saengboonmee, C. Wongkham, S. |
2019 |
Glycoconjugate Journal (), pp. |
Title | Authors | Year | Journal title |
---|
Title | Authors | Year | Journal title | Cited count | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
< 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | รวม |
Title | Authors | Year | Journal title |
---|
ชื่อโครงการ | Authors | ประเภทโครงการ | ปีงบประมาณ | ทุนวิจับ |
---|